← Leaderboards
Samuel Paul Brown
Georgia Institute Of Technology
$1,152,072
Attributed
$1,369,047
Total exposure
3
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $501.1K · FY2018–22$1M$750K$500K$250K$0
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$1,369,047 · 3
By mechanism
R21$867,900 · 2
R56$501,147 · 1
Top collaborators
- Marvin Whiteley2 shared
Most similar at Georgia Institute Of Technology
Same institution · by research overlap
- Cheng Zhu$26,173,441
- Gina Lewin$2,159,278
- Brittany N. Ross$100,115
Others in their field
Other Emerging Leaders on “Antibiotics”
- Urs Ochsner · Crestone, Inc.$36,950,837
- Ryan Cirz · Revagenix, Inc.$35,410,554
- Daniel Pevear · Venatorx Pharmaceuticals, Inc.$24,789,028
- Bruce Blough · Research Triangle Institute$19,637,160
- Thomas Dick · Rbhs-New Jersey Medical School$15,241,285
- Steven Armen Boyd · Venatorx Pharmaceuticals, Inc.$13,685,544
Research focus
AntibioticsBacteriaPseudomonas AeruginosaCystic FibrosisPathogenChronic InfectionPhenotypeIn VitroEvolutionGenotypeAntibiotic ResistanceBacteriophagesPharmaceutical PreparationsMedicalReceptorCystic Fibrosis PatientsResistanceGeneticAttentionClustered Regularly Interspaced Short Palindromic RepeatsMapsDiabetes MellitusInfectionChronic
Grant awards (5)
Building re-usable phage and antibiotic treatments via exploitation of bacteria-phage co-evolutionary dynamics$197,250
R21 · FY2022 · AI · contact PI
Building re-usable phage and antibiotic treatments via exploitation of bacteria-phage co-evolutionary dynamics$236,700
R21 · FY2021 · AI · contact PI
Phages as drivers of pathogenicity: selective impacts and molecular targets of clinical Pseudomonas aeruginosa phages$197,250
R21 · FY2020 · AI
Phages as drivers of pathogenicity: selective impacts and molecular targets of clinical Pseudomonas aeruginosa phages$236,700
R21 · FY2019 · AI
Bacterial regulatory evolution during adaptation to chronic infections$501,147
R56 · FY2018 · HL · contact PI